Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D'Avella

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
JAMA Network Open|November 5, 2021
Estimating Recurrence Risk in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung CancerChristopher D'Avella, J Nicholas Bodor
Urologic Oncology|November 28, 2018
Mutations in renal cell carcinomaChristopher D'Avella, Phillip Abbosh, Sumanta K Pal, et al.
JNCI Cancer Spectrum|February 20, 2024
The impact of an oncology urgent care center on health-care utilizationChristopher D'Avella, Peter Whooley, Emily Milano, et al.
Head & Neck|June 9, 2026
Clinicogenomic Features and Outcomes of Adenoid Cystic Carcinoma With Central Nervous System Metastases: A Single-Institution Cohort StudyOmar Elghawy, Jack Stylli, Martin Kurian, et al.
Journal of General Internal Medicine|January 8, 2020
Impact of Healthcare Delivery System Type on Clinical, Utilization, and Cost Outcomes of Patient-Centered Medical Homes: a Systematic ReviewClark A Veet, Thomas R Radomski, Christopher D'Avella, et al.
JAMA Otolaryngology-- Head & Neck Surgery|September 22, 2022
Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck CancerLova Sun, Danielle Candelieri-Surette, Tori Anglin-Foote, et al.
Clinical Lung Cancer|July 14, 2023
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimensWilliam P Tompkins, Wei-Ting Hwang, Yu-Xiao Yang, et al.
Clinical Lung Cancer|April 8, 2022
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and PemetrexedChristine A Ciunci, Jacob B Reibel, Tracey L Evans, et al.
Clinical Lung Cancer|January 1, 2025
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line TherapyOmar Elghawy, Adam Barsouk, Lauren Reed-Guy, et al.
JTO Clinical and Research Reports|August 11, 2025
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLCOmar Elghawy, Adam Barsouk, Jonathan H Sussman, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
JAMA Network Open|November 5, 2021
Estimating Recurrence Risk in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung CancerChristopher D'Avella, J Nicholas Bodor
Urologic Oncology|November 28, 2018
Mutations in renal cell carcinomaChristopher D'Avella, Phillip Abbosh, Sumanta K Pal, et al.
JNCI Cancer Spectrum|February 20, 2024
The impact of an oncology urgent care center on health-care utilizationChristopher D'Avella, Peter Whooley, Emily Milano, et al.
Head & Neck|June 9, 2026
Clinicogenomic Features and Outcomes of Adenoid Cystic Carcinoma With Central Nervous System Metastases: A Single-Institution Cohort StudyOmar Elghawy, Jack Stylli, Martin Kurian, et al.
Journal of General Internal Medicine|January 8, 2020
Impact of Healthcare Delivery System Type on Clinical, Utilization, and Cost Outcomes of Patient-Centered Medical Homes: a Systematic ReviewClark A Veet, Thomas R Radomski, Christopher D'Avella, et al.
JAMA Otolaryngology-- Head & Neck Surgery|September 22, 2022
Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck CancerLova Sun, Danielle Candelieri-Surette, Tori Anglin-Foote, et al.
Clinical Lung Cancer|July 14, 2023
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimensWilliam P Tompkins, Wei-Ting Hwang, Yu-Xiao Yang, et al.
Clinical Lung Cancer|April 8, 2022
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and PemetrexedChristine A Ciunci, Jacob B Reibel, Tracey L Evans, et al.
Clinical Lung Cancer|January 1, 2025
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line TherapyOmar Elghawy, Adam Barsouk, Lauren Reed-Guy, et al.
JTO Clinical and Research Reports|August 11, 2025
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLCOmar Elghawy, Adam Barsouk, Jonathan H Sussman, et al.
Pageof 2